Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its interim report for the period 1 January – 31 March 2026 on Thursday, 5 May 2026, at 8:00 a.m. CEST.
On the same day, Alligator will host a webinar and conference call for investors, analysts, and media at 1:00 p.m. CEST / 7:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session.
The call will be held in English. Attendees are required to register via >>this link<< and are welcome to submit questions in advance to ir@alligatorbioscience.com.
The full report will be available upon publication on Alligator’s website.